SEC Company Response from AIM ImmunoTech Inc. (AIM) (CIK 0000946644) (AIM) — Feb 11, 2019
AIM ImmunoTech Inc. (AIM) (CIK 0000946644)
Date: Feb. 11, 2019 · CIK: 0000946644 · Accession: 0001493152-19-001696
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229051
Letter
Re: Hemispherx Biopharma, Inc.
February 11, 2019
Securities and Exchange Commission
F Street, NE
Washington, DC 20002
Registration Statement on Form S-1
(SEC filing No. 333-229051)
Acceleration Request
Requested Date: February 14, 2019
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-229051) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin & Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.
Very
truly yours,
HEMISPHERX
BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
February
11, 2019
Securities
and Exchange Commission
100
F Street, NE
Washington,
DC 20002
Re:
Hemispherx
Biopharma, Inc.
Registration
Statement on Form S-1
(SEC
filing No. 333-229051)
Acceleration
Request
Requested
Date: February 14, 2019
Requested
Time: 4:00 P.M. Eastern Time
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Hemispherx Biopharma, Inc. (the “Company”) hereby requests
that the above-referenced Registration Statement on Form S-1 (File No. 333-229051) (the “Registration Statement”)
be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time
as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the
Securities and Exchange Commission.
Once
the Registration Statement has been declared effective, please orally confirm that event with our counsel, Silverman Shin &
Byrne PLLC, by calling Richard Feiner, Esq. at (646) 822-1170.
Very
truly yours,
HEMISPHERX
BIOPHARMA, INC.
By:
/s/
Adam Pascale
Adam
Pascale,
Chief
Financial Officer
cc:
Richard Feiner, Esq.
Corporate
Headquarters
2117
SW Highway 484, Ocala FL 34473
t:
407-839-0095
f:
407-839-2050
Finance
& Administration
600
Main Street, Suite 2, Riverton NJ 08077
t:
215-988-0080
f:
215-988-1739
Manufacturing
783
Jersey Ave, New Brunswick, NJ 08901
www.hemispherx.net
t:
732-249-3250
f:
732-249-6895